Olink® Flex

If you are tired of troubleshooting every step of your immunoassay workflow, upgrade with Olink® Flex. Find out how to freely mix and match biomarkers from a wide range of disease areas with 99% combinability. Skip washing steps and time-consuming dilution series with a streamlined protocol using the maintenance-free Olink® Signature Q100.

Discover the ultimate tool for multiplex protein analysis of precious samples. This white paper provides an overview of how Olink's proximity extension assay (PEA) technology has been used to measure 10s to 1000s of protein biomarkers from minute volumes of precious samples across major research areas, while delivering high data quality and robust performance.

Cytokine storm syndromes can be triggered by pathogens or multiple immune events, and are characterized by dysregulated systemic inflammation with excessive levels of circulating cytokines. Circulating cytokine monitoring has emerged as a critically informative, noninvasive tool. Analyzing cytokine signatures, rather than individual proteins, provides a more detailed and accurate picture of the underlying biology. Here, Olink presents the Olink® Flex Cytokine Storm panel, which includes pro- and anti-inflammatory molecules that are frequently monitored and found to be elevated in this pathological condition. It also features highly relevant cytokines that are present at low levels, thus often absent in most commercially available panels.

While immunotherapeutic approaches have achieved durable treatment responses in certain cancer patients and raise hope for further advancements, a lack of response and acquired drug resistance continue to pose major clinical challenges. Understanding the intricate mechanisms of tumor immune evasion is key to identifying novel druggable targets, as well as biomarkers that could lead to improved response prediction and patient stratification. Blood profiling based on an IFN signature can be relevant for predicting and following patient response to immunotherapy. Here, Olink presents the Olink® Flex IFN stimulation panel, which consists of 20 protein biomarkers, including CCL2, IL15 and L6, which have been shown as relevant for predicting response to immunotherapy. These biomarkers may be important both for understanding the context-dependent role of IFN stimulation in treatment response, as well as for developing personalized therapeutic strategies.

While the ground breaking success of immunotherapy has revolutionized cancer treatment, efforts to better predict responses and increase efficacy while reducing toxicity remain key challenges in the oncology field. Patient profiling based on blood biomarkers can have significant clinical value, due to the capacity of circulating proteins to provide real-time insights in a non-invasive, robust, and efficient manner. Here, Olink presents the Olink Flex Immuno-Oncology panel, which includes 21 proteins involved in various facets of tumor development and the immune response. Some of these biomakrers, such as IL8, LIF, IL6, TNFa, IFNγ and CXCL9/10/11, have been shown as clinically relevant for stratifying patients treated with immune checkpoint inhibitors.

In this application note, Olink Proteomics discusses the use of blood biomarker profiling to accelerate immunotherapy development. Olink also introduces the Olink Flex® Immuno-Oncology panel, which includes 21 proteins involved in tumor development and the immune response. Some of these biomarkers have shown clinical relevance in stratifying patients treated with immune checkpoint inhibitors. Blood biomarker profiling can provide real-time insights in a non-invasive, robust, and efficient manner for patient stratification, treatment response prediction, monitoring efficacy, and identifying immune-related adverse effects. Olink Flex technology allows for panel optimization and customization.

Here, Olink Proteomics presents a protein assay list for Olink® Flex. Olink® Flex empowers scientists with unprecedented freedom to analyze inflammatory pathways. With a library of more than 200 thoroughly pre-validated immune-related assays, markers of interest can be freely mixed and matched to create the perfect 21-plex panel to fit any specific research needs. Olink’s PEA technology assures consistent and reliable data quality in absolute quantification, with excellent specificity, sensitivity, and dynamic range. Costs and precious sample are saved by the robust system of internal controls that allows for singlicate sample analysis and by using just 1 µL per panel. Precarious and inconvenient washing steps and expensive maintenance are eliminated with Olink’s streamlined workflow and elegant instrument design.

Olink® Flex is a reagent kit measuring 15-21 selected human protein biomarkers simultaneously. The biomarkers are selected from a mix-and-match library of around 200 inflammation-related human proteins with 99 % combinability. Here, Olink Proteomics presents the results from the careful validation of the analytical performance of the product.

In this infographic, Olink Proteomics describes how you can freely mix and match inflammation-focused biomarkers with 99% combinability, using a protocol without washing steps and maintenance-free Olink® Signature Q100.

Hear from Professor Guillaume Paré from McMaster University, as he discusses the critical shift away from the traditional 'one biomarker, one disease' paradigm. He advocates for a more dynamic view of biomarkers, particularly focusing on protein signatures that can support better disease understanding and therapy development.

Olink is paving the way with its PEA technology to support the analysis of 5–5400+ proteins simultaneously. By working with an Olink Certified Service Provider such as CRLB-GMEL headed by Professor Guillaume Paré, investigators are enabled to redefine the boundaries of medical research and gain unique insights into disease biology, aiding the identification of new therapeutic targets and biomarkers.